01/11/2012 On January 11, 2012, the U.S. District Court for the Western District of Michigan entered an order finding Perrigo R&D’s generic extended-release guaifenesin tablet drug product does not infringe U.S. Patent No. 6,372,252. In the litigation, Adams Respiratory Therapeutics and Reckitt Benckiser, Inc. sought to prevent Perrigo R&D’s marketing of a generic equivalent to Mucinex® (guaifenesin) 600 mg. Perrigo R&D was able to secure a non-infringement victory on summary judgment on all asserted claims. Christine Siwik, William Rakoczy, and Alice Riechers are lead counsel for Perrigo. This victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.